Clinical observation of alprostadil combined with cilostazol in treatment of lower limb atherosclerosis

Objective To observe the curative effect of alprostadil combined with cilostazol in treatment of patients with lower limb atherosclerosis.Methods Sixty-two patients with lower limb atherosclerosis were divided into cilostazol group (cilostazol 100 mg,2 times a day,oral) and therapeutic alliance group (cilostazol 100 mg,2 times a day,oral; alprostadil 10 μ g dissolved in 100 ml intravenous infusion of 0.9％ sodium chloride,once a day) by random number table with 31 cases each.The changes of ankle-brachial index (ABI),distance of 6-minute walk test (6-MWT) and the dorsal blood flow were compared before and after treatment.Results | After treatment,the distance of 6-MWT,ABI and the level of dorsal blood flow were significantly improved in two groups (P ＜ 0.05 or ＜ 0.01 ).Distance of 6-MWT and the level of dorsal blood flow in therapeutic alliance group was significantly higher than that in cilostazol group after treatment [(425.4±138.5) m vs.(379.5±124.6) m,(0.77±0.18) ml/ (s·cm2) vs.(0.66±0.14) ml/( s· cm2)] ( P＜0.05 ).The total effective rate in the treatment of cold feel in therapeutic alliance group was significantly higher than that in cilostazol group [ 87.5％(21/24) vs.61.9％( 13/21 ) ](P＜ 0.05).Conclusion Alprostadil combined with cilostazol is safe and effective in treating lower limb atherosclerosis.